IGFBPL1抗体—艾普蒂

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Western blot analysis using EIF4E mouse mAb against Hela (1), HEK293 (2) and K562 (3) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of GC-7901 cells using EIF4E mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using EIF4E mouse mAb (green) and negative control (purple).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer (left) and submaxillary tumor (right) using EIF4E mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human stomach cancer (left) and prostate cancer (right) using EIF4E mouse mAb with DAB staining.    

  
  

The IGFBPL1 (Insulin-like growth factor binding protein-like 1) antibody is a tool used to detect and study the IGFBPL1 protein, a member of the insulin-like growth factor binding protein (IGFBP) family. IGFBPL1 shares structural homology with IGFBPs, which regulate IGF bioavailability and signaling, but its precise biological role remains less characterized. Emerging evidence suggests IGFBPL1 may influence cellular processes such as proliferation, apoptosis, and metabolism, potentially interacting with pathways beyond the IGF axis, including extracellular matrix remodeling and immune regulation.

This antibody is primarily utilized in research applications like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to map IGFBPL1 expression patterns in tissues or cell lines. Studies have reported its involvement in diseases, including certain cancers (e.g., breast, liver) and metabolic disorders, where altered IGFBPL1 levels correlate with pathological progression. Commercial IGFBPL1 antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes within the protein’s conserved regions. Validation data, including knockout controls or siRNA silencing, are critical to confirm antibody specificity due to potential cross-reactivity with other IGFBP family members. Ongoing research aims to clarify IGFBPL1’s mechanistic roles and therapeutic potential, driving demand for reliable detection tools.